AstraZeneca announced that the company has set up manufacturing capacity to produce two billion doses of the Oxford’s potential COVID-19 vaccine.
The pharma firm has committed to supply 400 million doses for the US and UK upon reaching a licence agreement with the Oxford University for its vaccine.
Oxford and AstraZeneca have also entered a partnership with Serum Institute of India (SII) to supply one billion doses for low-and-middle-income countries.
The company also has reached a $750m agreement with international organisations such as the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi the Vaccine Alliance to support the manufacturing, procurement and distribution of 300 million doses of the vaccine, with delivery starting by the end of the year, ensuring global access to the vaccine.
The recombinant adenovirus-based vaccine formerly called ChAdOx1 nCoV-19 is now known as AZD1222 and is currently undergoing phase2/3 trial in about 10,260 adults and children across the UK.
Recently, the Brazilian Health Regulatory Agency (ANVISA) has also approved the testing of the vaccine on 2,000 Brazilian volunteers.